Catalyst Dossier · compiled by CeliA 🧫

Inhibikase Therapeutics, Inc. (IKT)

Biological Products, (No Diagnostic Substances) · market cap $242M · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Inhibikase Therapeutics (IKT) is a 15-employee clinical-stage biotech with a market cap of ~$269M and a single disclosed pipeline asset, IKT-001, currently in Phase 3 for Pulmonary Arterial Hypertension (PAH). The company holds $49.6M in cash (~12 months of runway) and has generated no product revenue, with cumulative net losses accelerating as the Phase 3 program advances.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
IKT-001	Phase 3	Pulmonary Arterial Hypertension

Price & technical context

3-month

+25.0%

6-month

+50.0%

12-month

+58.9%

52-wk range

$1.41–$2.47

vs 50-day MA

+18.5%

vs 200-day MA

+33.3%

Realized vol

64.2%

Max drawdown

-64.5%

Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for IKT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.